These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 23666879)

  • 41. The generation, detection, and effects of reactive drug metabolites.
    Stachulski AV; Baillie TA; Park BK; Obach RS; Dalvie DK; Williams DP; Srivastava A; Regan SL; Antoine DJ; Goldring CE; Chia AJ; Kitteringham NR; Randle LE; Callan H; Castrejon JL; Farrell J; Naisbitt DJ; Lennard MS
    Med Res Rev; 2013 Sep; 33(5):985-1080. PubMed ID: 23090860
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The role of binding kinetics in therapeutically useful drug action.
    Swinney DC
    Curr Opin Drug Discov Devel; 2009 Jan; 12(1):31-9. PubMed ID: 19152211
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An Integrated Approach for Assessing the Impact of Renal Impairment on Pharmacokinetics of Drugs in Development: Pivotal Role of PBPK Modelling.
    Rowland Yeo K; Gil Berglund E
    Clin Pharmacol Ther; 2021 Nov; 110(5):1168-1171. PubMed ID: 33934342
    [No Abstract]   [Full Text] [Related]  

  • 44. FDA drug prescribing warnings: is the black box half empty or half full?
    Wagner AK; Chan KA; Dashevsky I; Raebel MA; Andrade SE; Lafata JE; Davis RL; Gurwitz JH; Soumerai SB; Platt R
    Pharmacoepidemiol Drug Saf; 2006 Jun; 15(6):369-86. PubMed ID: 16294363
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical pharmacokinetics: current requirements and future perspectives from a regulatory point of view.
    Shah RR
    Xenobiotica; 1993 Nov; 23(11):1159-93. PubMed ID: 8310705
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A review of the common properties of drugs with idiosyncratic hepatotoxicity and the "multiple determinant hypothesis" for the manifestation of idiosyncratic drug toxicity.
    Li AP
    Chem Biol Interact; 2002 Nov; 142(1-2):7-23. PubMed ID: 12399152
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The importance of drug-target residence time.
    Zhang R; Monsma F
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):488-96. PubMed ID: 19562645
    [TBL] [Abstract][Full Text] [Related]  

  • 48. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance.
    Ring BJ; Chien JY; Adkison KK; Jones HM; Rowland M; Jones RD; Yates JW; Ku MS; Gibson CR; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Poulin P
    J Pharm Sci; 2011 Oct; 100(10):4090-110. PubMed ID: 21541938
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Addressing toxicity risk when designing and selecting compounds in early drug discovery.
    Segall MD; Barber C
    Drug Discov Today; 2014 May; 19(5):688-93. PubMed ID: 24451294
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Advances in molecular toxicology-towards understanding idiosyncratic drug toxicity.
    Park BK; Kitteringham NR; Powell H; Pirmohamed M
    Toxicology; 2000 Nov; 153(1-3):39-60. PubMed ID: 11090946
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Use of radiolabeled compounds in drug metabolism and pharmacokinetic studies.
    Isin EM; Elmore CS; Nilsson GN; Thompson RA; Weidolf L
    Chem Res Toxicol; 2012 Mar; 25(3):532-42. PubMed ID: 22372867
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Benchmarking in vitro covalent binding burden as a tool to assess potential toxicity caused by nonspecific covalent binding of covalent drugs.
    Dahal UP; Obach RS; Gilbert AM
    Chem Res Toxicol; 2013 Nov; 26(11):1739-45. PubMed ID: 24164572
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies.
    Bauer RA
    Drug Discov Today; 2015 Sep; 20(9):1061-73. PubMed ID: 26002380
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chemical toxicology: reactive intermediates and their role in pharmacology and toxicology.
    Erve JC
    Expert Opin Drug Metab Toxicol; 2006 Dec; 2(6):923-46. PubMed ID: 17125409
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evidence supporting the need for considering the effects of smoking on drug disposition and effectiveness in medication practices: a systematic narrative review.
    Sohn HS; Kim H; Song IS; Lim E; Kwon M; Ha JH; Kwon JW
    Int J Clin Pharmacol Ther; 2015 Aug; 53(8):621-34. PubMed ID: 26104035
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Drug interactions. Mechanisms and clinical relevance].
    Klotz U; Beil W; Gleiter C; Drewelow B; Garbe E; Gillessen A; Mutschler E
    Internist (Berl); 2003 Nov; 44(11):1444-9. PubMed ID: 14689079
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of physiologically based pharmacokinetic modeling and simulation in drug development.
    Shardlow CE; Generaux GT; Patel AH; Tai G; Tran T; Bloomer JC
    Drug Metab Dispos; 2013 Dec; 41(12):1994-2003. PubMed ID: 24009310
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Screening for the potential of a drug candidate to cause idiosyncratic drug reactions.
    Uetrecht J
    Drug Discov Today; 2003 Sep; 8(18):832-7. PubMed ID: 12963319
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Idiosyncratic reactions and metabolism of sulfur-containing drugs.
    Zuniga FI; Loi D; Ling KH; Tang-Liu DD
    Expert Opin Drug Metab Toxicol; 2012 Apr; 8(4):467-85. PubMed ID: 22394356
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Toward a new age of cellular pharmacokinetics in drug discovery.
    Zhou F; Zhang J; Li P; Niu F; Wu X; Wang G; Roberts MS
    Drug Metab Rev; 2011 Aug; 43(3):335-45. PubMed ID: 21395404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.